Search This Blog

Thursday, November 21, 2024

Amneal FDA OK for Exenatide, its First Generic Injectable GLP-1 Agonist

 Potential first and only DHE autoinjector for tough-to-treat migraines and cluster headaches

Exenatide approval highlights Amneal’s capabilities in developing GLP-1 injectables

https://www.businesswire.com/news/home/20241121053036/en/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.